Home-Based Biofeedback for Fecal Incontinence: A Randomized Clinical Trial

居家生物反馈治疗大便失禁:一项随机临床试验

阅读:2

Abstract

IMPORTANCE: Access to biofeedback, a first-line treatment for fecal incontinence (FI), is limited. OBJECTIVE: The objective of this study was to evaluate whether an 8-week duration of a home-based digital therapeutic pelvic health system to treat FI in women is equivalent to a 16-week duration. STUDY DESIGN: We conducted a single-blind, randomized, equivalence trial in women with FI. Participants were randomized to 8 or 16 weeks of twice-daily exercises using the system and could opt to participate in remote health coaching. The primary outcome was the change in FI severity as measured by the Vaizey score from baseline to 16 weeks. Our target sample size was 15 participants per arm. Paired t test, χ2 test, and McNemar-Bowker test compared differences over time and between groups. RESULTS: Among 38 women enrolled, 36 (18 per arm) provided complete data. All received allocated treatment, with a mean adherence of 75.2%. Most participants identified as non-Hispanic White (97.3%), with a mean age of 62.4 ± 15.4 years and a mean body mass index 29.5 ± 8.9. Baseline FI severity was high and improved significantly over time in both groups. Treatment duration of 8 weeks was equivalent to 16 weeks with changes in Vaizey scores that reached the minimal clinically important difference in both groups (-4.7 ± 5.1 vs -4.8 ± 4.5, P = 0.918). CONCLUSIONS: FI outcomes improved significantly with a home-based pelvic health system with biofeedback and remote health coaching used for either 8 or 16 weeks, without significant differences between groups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。